Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
US FDA approves GSK's urinary tract infection drug
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.
GSK studying if best-selling shingles vaccine lowers dementia risk
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
GSK says European regulator reviewing expanded use of asthma drug Nucala
GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK plc (GSK) TD Cowen 45th Annual Health Care Conference (Transcript)
GSK plc (NYSE:GSK ) TD Cowen 45th Annual Health Care Conference March 3, 2024 9:50 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have GSK at the TD Cowen Conference once again this year.
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
On Monday, the Food and Drug Administration (FDA) accepted for review GSK plc's GSK marketing application for depemokimab in two indications.
